-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent months, the new crown pneumonia epidemic has once again become the focus of public attention
.
As the number of infections climbed, the sales prices of Chinese patent medicines recommended in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9)" (hereinafter referred to as the "Diagnosis and Treatment Plan") on e-commerce platforms began to rise
.
Consumer side: Rising demand: Raising sales prices Beginning in March 2020, the overall market for Chinese patent medicines recommended in the "Diagnosis and Treatment Plan" began to fluctuate continuously
.
Among them, Huoxiangzhengqi Capsules remained in the price range of 14.
00-16.
00 yuan, Lianhua Qingwen Capsules remained at 21.
80-29.
60 yuan, and Shufengjiedu capsules remained at 36.
00-42.
00 yuan
.
Through the comparison in Figure 1, it is found that the sales price fluctuations of the three kinds of proprietary Chinese medicines fluctuated to a large extent before and after the epidemic
.
The first change: From June to July 2020, at the beginning of the unblocking of the epidemic, the country resumed work one after another, the social demand increased greatly in the short term, and the sales prices of various platforms also began to rise rapidly
.
The second change: November 2020-April 2021 and November 2021-January 2022, during the high-incidence period of the national flu, social drugs have increased, and the market has changed significantly
.
Winter is a period of high incidence of respiratory diseases, the amount of drugs used in society increases steadily, and the prices of various platforms continue to rise
.
The third change: From March to April 2022, the new crown pneumonia epidemic in many places in China has resurfaced, and the number of drugs for diagnosis and treatment has increased significantly
.
Jilin, Shanghai, Guangdong and other provinces have experienced a rapid increase in the number of infected groups in a short period of time, and social drugs have increased again.
At the same time, the prices of various platforms have also been adjusted due to the tight supply of goods during this period
.
Through comparison, we found that since June 2021, the average prices of these proprietary Chinese medicines on various platforms have generally been higher than in 2020
.
The rise in the price of Chinese patent medicines is due to the tight supply of social demand on the one hand, and the impact of the increase in the cost of production raw materials on the other hand.
.
Production side: supply of raw materials: affecting production costs From June 2021 to the present, the production costs of Huoxiangzhengqi Capsules, Lianhua Qingwen Capsules and Shufeng Jiedu Capsules have shown a fluctuating upward trend
.
Among them, the production cost of Huoxiangzhengqi capsules rose from 22.
90 yuan in June 2021 to 23.
64 yuan in April 2022, an increase of 3.
23%; the production cost of Lianhua Qingwen rose from 38.
15 yuan in June 2021 to April 2022 The production cost of Shufeng Jiedu capsules increased from 24.
52 yuan in June 2021 to 32.
55 yuan in April 2022, an increase of 32.
75%
.
From Figure 2, we can find that the production costs of the three Chinese patent medicines will usher in a small correction from September 2021 to February 2022
.
For Huoxiangzhengqi Capsules, the decline in the prices of dried ginger, Pinellia and Patchouli is the key to its production cost adjustment; for Lianhua Qingwen Capsules, the key to its production cost adjustment is Patchouli, Mianma Guanzhong and Hongjing.
Sky, Houttuynia cordata, menthol and honeysuckle prices fell; for Shufengjiedu capsules, the fall in the price of Verbena was the key to its production cost correction
.
Beginning in February 2022, various production enterprises began to purchase raw materials for the new year, and the supply of epidemic prevention raw materials was tight in a short period of time.
At the same time, with the outbreak of the epidemic in Jilin Province in March, the raw materials required for the three kinds of proprietary Chinese medicines showed relatively low overall.
The tense situation, especially the raw materials involving Forsythia, Banlangen, bitter almond, Platycodon, Atractylodes and other varieties, continue to drive up production costs
.
At present, the market of Chinese medicinal materials related to epidemic prevention is still fluctuating, for example: Forsythia: The annual demand remains at 8,500 tons
.
In 2021, due to the influence of weather and rainfall, the harvest area that year was less than 80,000 mu, a decrease of 38.
61% compared with 2020
.
At the same time, affected by the new crown pneumonia epidemic this year, the social inventory of Forsythia has been fully digested
.
Under the influence of weak inventory, declining production capacity and rapid increase in demand, the forsythia market began to sing all the way
.
Before this year's new production, the forsythia market is still strong and rising
.
Honeysuckle: The annual demand remains at 12,000 tons
.
In recent years, affected by the continuous rise of the honeysuckle market, the planting enthusiasm in various production areas across the country has continued to rise, especially in provinces supported by poverty alleviation policies, the planting area has grown rapidly
.
In 2021, the national planting area will exceed 450,000 mu, an increase of 13.
07% compared with 2020, and the output of the year has also increased significantly
.
As the honeysuckle plants planted in recent years have gradually ushered in a prolific period, the overcapacity situation will become prominent in the future.
It is expected that the honeysuckle market will still show a downward trend after new production this year
.
Patchouli: Annual demand remains at 2,500 tons
.
In 2020, the social demand for medicines due to the epidemic has risen rapidly.
Due to the low price market for many years, the production in the production area has been severely reduced, resulting in a serious shortage of supply in 2020
.
At the same time, as the market continues to rise, various production areas have begun to increase production.
In 2021, the planting area of patchouli will exceed 100,000 mu, an increase of 97.
65% compared with 2020.
As a result, the market will plunge in May 2021.
.
Although the current market price has fallen to the production cost, due to the serious expansion of the planting area, it is expected that the market will still fall after the new crop is produced this year
.
Campanulaceae: The annual demand remains at 23,000 tons
.
In 2021, due to the influence of weather and rainfall, the harvest area that year was less than 140,000 mu, a decrease of 7.
06% compared with 2020
.
At the same time, due to the increase in the use of drugs for the new crown pneumonia epidemic in 2021, the social inventory of Campanulaceae has been fully digested
.
Under the influence of weak inventory, declining production capacity and rapid increase in demand, the market of Campanulaceae began to rise rapidly
.
As the production of bellflower has continued to increase in recent years, it is expected that before the new production this year, the market will fluctuate due to changes in the epidemic
.
Summary This time the price of proprietary Chinese medicines has risen, and the rapid growth of social demand in the short term is the driving force behind it, but the recent rise in production raw materials to varying degrees is the fundamental reason for its price rise.
Therefore, at this stage, the overall market will still show shocks and move forward.
.
The consumption-side medicines have obvious periodicity, and should try to avoid the peak period of purchase.
The high-incidence period of respiratory system diseases is generally related to climate change.
Therefore, as the consumer side, the procurement of respiratory system disease medicines should try to avoid the high-incidence period of the disease
.
Purchasing in a period of abundant supply can effectively reduce the relevant procurement costs on the one hand, and on the other hand, it can also avoid the situation that drugs cannot be purchased in time during the peak period of drug use
.
Raw material production also has obvious cycle characteristics, and raw material storage should be carried out in suitable stages and methods
.
Raw material reserves should be scientifically planned according to different production varieties.
For varieties with short growth cycles, they can be stored on demand in the form of flow; for varieties with long growth cycles, medium and long-term reserves can be made in the form of orders, which can effectively prevent abnormal changes in raw materials.
Insufficient supply
.
.
As the number of infections climbed, the sales prices of Chinese patent medicines recommended in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9)" (hereinafter referred to as the "Diagnosis and Treatment Plan") on e-commerce platforms began to rise
.
Consumer side: Rising demand: Raising sales prices Beginning in March 2020, the overall market for Chinese patent medicines recommended in the "Diagnosis and Treatment Plan" began to fluctuate continuously
.
Among them, Huoxiangzhengqi Capsules remained in the price range of 14.
00-16.
00 yuan, Lianhua Qingwen Capsules remained at 21.
80-29.
60 yuan, and Shufengjiedu capsules remained at 36.
00-42.
00 yuan
.
Through the comparison in Figure 1, it is found that the sales price fluctuations of the three kinds of proprietary Chinese medicines fluctuated to a large extent before and after the epidemic
.
The first change: From June to July 2020, at the beginning of the unblocking of the epidemic, the country resumed work one after another, the social demand increased greatly in the short term, and the sales prices of various platforms also began to rise rapidly
.
The second change: November 2020-April 2021 and November 2021-January 2022, during the high-incidence period of the national flu, social drugs have increased, and the market has changed significantly
.
Winter is a period of high incidence of respiratory diseases, the amount of drugs used in society increases steadily, and the prices of various platforms continue to rise
.
The third change: From March to April 2022, the new crown pneumonia epidemic in many places in China has resurfaced, and the number of drugs for diagnosis and treatment has increased significantly
.
Jilin, Shanghai, Guangdong and other provinces have experienced a rapid increase in the number of infected groups in a short period of time, and social drugs have increased again.
At the same time, the prices of various platforms have also been adjusted due to the tight supply of goods during this period
.
Through comparison, we found that since June 2021, the average prices of these proprietary Chinese medicines on various platforms have generally been higher than in 2020
.
The rise in the price of Chinese patent medicines is due to the tight supply of social demand on the one hand, and the impact of the increase in the cost of production raw materials on the other hand.
.
Production side: supply of raw materials: affecting production costs From June 2021 to the present, the production costs of Huoxiangzhengqi Capsules, Lianhua Qingwen Capsules and Shufeng Jiedu Capsules have shown a fluctuating upward trend
.
Among them, the production cost of Huoxiangzhengqi capsules rose from 22.
90 yuan in June 2021 to 23.
64 yuan in April 2022, an increase of 3.
23%; the production cost of Lianhua Qingwen rose from 38.
15 yuan in June 2021 to April 2022 The production cost of Shufeng Jiedu capsules increased from 24.
52 yuan in June 2021 to 32.
55 yuan in April 2022, an increase of 32.
75%
.
From Figure 2, we can find that the production costs of the three Chinese patent medicines will usher in a small correction from September 2021 to February 2022
.
For Huoxiangzhengqi Capsules, the decline in the prices of dried ginger, Pinellia and Patchouli is the key to its production cost adjustment; for Lianhua Qingwen Capsules, the key to its production cost adjustment is Patchouli, Mianma Guanzhong and Hongjing.
Sky, Houttuynia cordata, menthol and honeysuckle prices fell; for Shufengjiedu capsules, the fall in the price of Verbena was the key to its production cost correction
.
Beginning in February 2022, various production enterprises began to purchase raw materials for the new year, and the supply of epidemic prevention raw materials was tight in a short period of time.
At the same time, with the outbreak of the epidemic in Jilin Province in March, the raw materials required for the three kinds of proprietary Chinese medicines showed relatively low overall.
The tense situation, especially the raw materials involving Forsythia, Banlangen, bitter almond, Platycodon, Atractylodes and other varieties, continue to drive up production costs
.
At present, the market of Chinese medicinal materials related to epidemic prevention is still fluctuating, for example: Forsythia: The annual demand remains at 8,500 tons
.
In 2021, due to the influence of weather and rainfall, the harvest area that year was less than 80,000 mu, a decrease of 38.
61% compared with 2020
.
At the same time, affected by the new crown pneumonia epidemic this year, the social inventory of Forsythia has been fully digested
.
Under the influence of weak inventory, declining production capacity and rapid increase in demand, the forsythia market began to sing all the way
.
Before this year's new production, the forsythia market is still strong and rising
.
Honeysuckle: The annual demand remains at 12,000 tons
.
In recent years, affected by the continuous rise of the honeysuckle market, the planting enthusiasm in various production areas across the country has continued to rise, especially in provinces supported by poverty alleviation policies, the planting area has grown rapidly
.
In 2021, the national planting area will exceed 450,000 mu, an increase of 13.
07% compared with 2020, and the output of the year has also increased significantly
.
As the honeysuckle plants planted in recent years have gradually ushered in a prolific period, the overcapacity situation will become prominent in the future.
It is expected that the honeysuckle market will still show a downward trend after new production this year
.
Patchouli: Annual demand remains at 2,500 tons
.
In 2020, the social demand for medicines due to the epidemic has risen rapidly.
Due to the low price market for many years, the production in the production area has been severely reduced, resulting in a serious shortage of supply in 2020
.
At the same time, as the market continues to rise, various production areas have begun to increase production.
In 2021, the planting area of patchouli will exceed 100,000 mu, an increase of 97.
65% compared with 2020.
As a result, the market will plunge in May 2021.
.
Although the current market price has fallen to the production cost, due to the serious expansion of the planting area, it is expected that the market will still fall after the new crop is produced this year
.
Campanulaceae: The annual demand remains at 23,000 tons
.
In 2021, due to the influence of weather and rainfall, the harvest area that year was less than 140,000 mu, a decrease of 7.
06% compared with 2020
.
At the same time, due to the increase in the use of drugs for the new crown pneumonia epidemic in 2021, the social inventory of Campanulaceae has been fully digested
.
Under the influence of weak inventory, declining production capacity and rapid increase in demand, the market of Campanulaceae began to rise rapidly
.
As the production of bellflower has continued to increase in recent years, it is expected that before the new production this year, the market will fluctuate due to changes in the epidemic
.
Summary This time the price of proprietary Chinese medicines has risen, and the rapid growth of social demand in the short term is the driving force behind it, but the recent rise in production raw materials to varying degrees is the fundamental reason for its price rise.
Therefore, at this stage, the overall market will still show shocks and move forward.
.
The consumption-side medicines have obvious periodicity, and should try to avoid the peak period of purchase.
The high-incidence period of respiratory system diseases is generally related to climate change.
Therefore, as the consumer side, the procurement of respiratory system disease medicines should try to avoid the high-incidence period of the disease
.
Purchasing in a period of abundant supply can effectively reduce the relevant procurement costs on the one hand, and on the other hand, it can also avoid the situation that drugs cannot be purchased in time during the peak period of drug use
.
Raw material production also has obvious cycle characteristics, and raw material storage should be carried out in suitable stages and methods
.
Raw material reserves should be scientifically planned according to different production varieties.
For varieties with short growth cycles, they can be stored on demand in the form of flow; for varieties with long growth cycles, medium and long-term reserves can be made in the form of orders, which can effectively prevent abnormal changes in raw materials.
Insufficient supply
.
